Hair thinning during perimenopause and menopause affects roughly 40% of women to some degree. Some of it is reversible hormonal effect; some is the unmasking of underlying female pattern hair loss. Telling them apart matters.
During reproductive years, elevated estrogen counterbalances the modest androgen levels women produce. Estrogen extends the active growth phase of hair follicles, which is part of why women generally maintain better hair density than men through their thirties and forties.
At menopause, estrogen falls sharply while androgen levels remain steady or fall more slowly. The androgen-to-estrogen ratio shifts — and follicles that are genetically susceptible to androgen-driven miniaturisation are no longer protected. The result: gradual diffuse thinning, often most visible at the part line and the front of the scalp.
Some women experience this as a transient telogen effluvium-style shed during perimenopause that resolves over twelve to eighteen months. Others see persistent thinning that reflects underlying female pattern hair loss being unmasked by the hormonal shift.
Both look similar at first — diffuse thinning across the top of the scalp. The distinction matters because the treatment paths are different:
Hormonal (telogen effluvium-style): Onset coincides with perimenopausal symptoms (irregular periods, hot flashes, mood changes). Often improves with hormone replacement therapy if appropriate, or resolves on its own as the body adapts. Bloodwork rules out thyroid, iron, and vitamin D contributors.
Genetic (female pattern hair loss): Family history of female pattern in mother, sisters, aunts. Pattern is more concentrated at the part line, sometimes with widening of the central part over time. Doesn’t resolve on its own — needs ongoing treatment.
A trichoscopy exam or photo consultation can usually distinguish the two, particularly if you have photos from before menopause to compare.
For hormonal shedding: Discuss hormone replacement therapy (HRT) with your physician — it isn’t a hair-loss treatment per se, but it sometimes resolves perimenopausal hair shedding as a side effect. Bloodwork to rule out reversible contributors (thyroid, iron, vitamin D). Time and patience for the body to adapt.
For genetic FPHL unmasked by menopause: Topical or oral minoxidil is the first-line medical treatment. Oral spironolactone is sometimes prescribed off-label for its anti-androgen effect. Low-dose oral minoxidil (1.25mg) is increasingly used. PRP can support existing follicles.
Surgery (for stable, well-defined cases): Female hair transplant is appropriate when the loss has stabilised, donor density is adequate, and the cause is genuinely androgenetic. The diagnosis comes first; the surgical plan follows.
Photo submission with a brief history (when did the change start, family history of pattern loss, current symptoms). Dr. Jones reviews personally and recommends the right diagnostic path — bloodwork, trichology, or directly to a treatment plan if the diagnosis is clear.